Last reviewed · How we verify
OxyNorm
OxyNorm is an immediate-release oral formulation of oxycodone that binds to opioid receptors in the central nervous system to provide rapid pain relief.
OxyNorm is an immediate-release oral formulation of oxycodone that binds to opioid receptors in the central nervous system to provide rapid pain relief. Used for Moderate to severe acute pain, Breakthrough pain in opioid-tolerant patients.
At a glance
| Generic name | OxyNorm |
|---|---|
| Also known as | oral medication consisting of Oxycodonhydrochlorid |
| Sponsor | Kures, Inc. |
| Drug class | Opioid analgesic |
| Target | Mu (μ) opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Oxycodone is a semi-synthetic opioid agonist that acts primarily on mu (μ) opioid receptors in the brain and spinal cord. The immediate-release formulation allows for quick absorption and onset of analgesia, making it suitable for acute or breakthrough pain management. It works by modulating pain perception and emotional response to pain through central nervous system depression.
Approved indications
- Moderate to severe acute pain
- Breakthrough pain in opioid-tolerant patients
Common side effects
- Constipation
- Nausea
- Dizziness
- Drowsiness
- Vomiting
- Pruritus
Key clinical trials
- METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation (HYPNOLUX) (PHASE4)
- Shoulder Denervation for Post Mastectomy Irradiation Shoulder Pain (NA)
- Multimodal Versus Opioid aNalgesia in carDiAc Surgery (PHASE4)
- Influence of Oxycodone on Individuals Taking an SSRI (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of KUR-101 in Healthy Adults (PHASE1)
- NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers (PHASE3)
- Population Pharmacokinetic-Pharmacodynamic Study of Intravenous Oxycodone in Malaysian Population (PHASE4)
- Opioids Titration Study in Advanced Cancer Patients in Hong Kong (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OxyNorm CI brief — competitive landscape report
- OxyNorm updates RSS · CI watch RSS
- Kures, Inc. portfolio CI